OA10711A - Triazole derivatives useful in therapy. - Google Patents

Triazole derivatives useful in therapy. Download PDF

Info

Publication number: OA10711A
Authority: OA; OAPI
Prior art keywords: compound; formula; mmol; solution; sait
Prior art date: 1996-02-02

Application number

OA9800110A

Other languages

English (en)

Inventor

Charles W Murtiashaw

Stuart Green

Peter T Stephenson

Original Assignee

Pfizer Res & Dev

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1996-02-02

Filing date

1998-07-10

Publication date

2001-06-04

1998-07-10 Application filed by Pfizer Res & Dev filed Critical Pfizer Res & Dev

2001-06-04 Publication of OA10711A publication Critical patent/OA10711A/en

Links

238000002560 therapeutic procedure Methods 0.000 title description 3
229940042055 systemic antimycotics triazole derivative Drugs 0.000 title 1
150000001875 compounds Chemical class 0.000 claims abstract description 87
125000002887 hydroxy group Chemical group [H]O* 0.000 claims abstract description 12
150000003852 triazoles Chemical class 0.000 claims abstract description 9
206010017533 Fungal infection Diseases 0.000 claims abstract description 8
208000031888 Mycoses Diseases 0.000 claims abstract description 8
229940121375 antifungal agent Drugs 0.000 claims abstract description 8
230000000843 anti-fungal effect Effects 0.000 claims abstract description 7
238000011282 treatment Methods 0.000 claims abstract description 7
239000000203 mixture Substances 0.000 claims description 28
238000000034 method Methods 0.000 claims description 10
125000000325 methylidene group Chemical group [H]C([H])=* 0.000 claims description 9
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 8
206010011416 Croup infectious Diseases 0.000 claims description 5
201000010549 croup Diseases 0.000 claims description 5
238000009472 formulation Methods 0.000 claims description 4
229910052736 halogen Inorganic materials 0.000 claims description 4
150000002367 halogens Chemical class 0.000 claims description 4
238000004519 manufacturing process Methods 0.000 claims description 4
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 4
125000000623 heterocyclic group Chemical group 0.000 claims description 3
239000002671 adjuvant Substances 0.000 claims description 2
239000003085 diluting agent Substances 0.000 claims description 2
125000005843 halogen group Chemical group 0.000 claims description 2
QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims description 2
230000000865 phosphorylative effect Effects 0.000 claims description 2
125000000335 thiazolyl group Chemical group 0.000 claims description 2
125000001425 triazolyl group Chemical group 0.000 claims description 2
125000004215 2,4-difluorophenyl group Chemical group [H]C1=C([H])C(*)=C(F)C([H])=C1F 0.000 claims 1
241001550224 Apha Species 0.000 claims 1
GHJWNRRCRIGGIO-UHFFFAOYSA-N Fosfluconazole Chemical compound C1=NC=NN1CC(C=1C(=CC(F)=CC=1)F)(OP(O)(=O)O)CN1C=NC=N1 GHJWNRRCRIGGIO-UHFFFAOYSA-N 0.000 claims 1
125000000714 pyrimidinyl group Chemical group 0.000 claims 1
150000003839 salts Chemical class 0.000 abstract description 5
YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 45
239000000243 solution Substances 0.000 description 45
XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 42
VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 30
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 28
CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 22
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 21
239000000047 product Substances 0.000 description 19
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 15
IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 15
229910019142 PO4 Inorganic materials 0.000 description 14
229940093499 ethyl acetate Drugs 0.000 description 14
235000019439 ethyl acetate Nutrition 0.000 description 14
239000010452 phosphate Substances 0.000 description 14
238000005160 1H NMR spectroscopy Methods 0.000 description 13
239000007787 solid Substances 0.000 description 13
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 12
YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 12
229940073584 methylene chloride Drugs 0.000 description 12
NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 12
229910052943 magnesium sulfate Inorganic materials 0.000 description 11
235000019341 magnesium sulphate Nutrition 0.000 description 11
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 9
KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 9
230000002829 reductive effect Effects 0.000 description 9
239000002904 solvent Substances 0.000 description 9
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 8
WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 6
CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 6
JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 6
238000006243 chemical reaction Methods 0.000 description 6
229910052757 nitrogen Inorganic materials 0.000 description 6
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 5
UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 5
239000000284 extract Substances 0.000 description 5
239000011541 reaction mixture Substances 0.000 description 5
238000010992 reflux Methods 0.000 description 5
NHQDETIJWKXCTC-UHFFFAOYSA-N 3-chloroperbenzoic acid Chemical compound OOC(=O)C1=CC=CC(Cl)=C1 NHQDETIJWKXCTC-UHFFFAOYSA-N 0.000 description 4
VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 4
NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 4
WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 4
241000222122 Candida albicans Species 0.000 description 4
VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 4
239000002253 acid Substances 0.000 description 4
239000008346 aqueous phase Substances 0.000 description 4
BTANRVKWQNVYAZ-UHFFFAOYSA-N butan-2-ol Chemical compound CCC(C)O BTANRVKWQNVYAZ-UHFFFAOYSA-N 0.000 description 4
229940095731 candida albicans Drugs 0.000 description 4
239000003054 catalyst Substances 0.000 description 4
238000004440 column chromatography Methods 0.000 description 4
238000001914 filtration Methods 0.000 description 4
239000000499 gel Substances 0.000 description 4
208000015181 infectious disease Diseases 0.000 description 4
239000000741 silica gel Substances 0.000 description 4
229910002027 silica gel Inorganic materials 0.000 description 4
239000002002 slurry Substances 0.000 description 4
239000001632 sodium acetate Substances 0.000 description 4
235000017281 sodium acetate Nutrition 0.000 description 4
239000000725 suspension Substances 0.000 description 4
239000006188 syrup Substances 0.000 description 4
235000020357 syrup Nutrition 0.000 description 4
BCEHBSKCWLPMDN-MGPLVRAMSA-N voriconazole Chemical compound C1([C@H](C)[C@](O)(CN2N=CN=C2)C=2C(=CC(F)=CC=2)F)=NC=NC=C1F BCEHBSKCWLPMDN-MGPLVRAMSA-N 0.000 description 4
238000005406 washing Methods 0.000 description 4
-1 2,6-dichlorobenzyl Chemical group 0.000 description 3
QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 3
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
241001225321 Aspergillus fumigatus Species 0.000 description 3
VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 3
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
241000282414 Homo sapiens Species 0.000 description 3
MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 3
MZRVEZGGRBJDDB-UHFFFAOYSA-N N-Butyllithium Chemical compound [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 description 3
QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 3
230000002411 adverse Effects 0.000 description 3
229940091771 aspergillus fumigatus Drugs 0.000 description 3
239000012267 brine Substances 0.000 description 3
239000003795 chemical substances by application Substances 0.000 description 3
NBIIXXVUZAFLBC-UHFFFAOYSA-M dihydrogenphosphate Chemical compound OP(O)([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-M 0.000 description 3
230000000694 effects Effects 0.000 description 3
239000006260 foam Substances 0.000 description 3
238000001727 in vivo Methods 0.000 description 3
239000010410 layer Substances 0.000 description 3
ANPWLBTUUNFQIO-UHFFFAOYSA-N n-bis(phenylmethoxy)phosphanyl-n-propan-2-ylpropan-2-amine Chemical compound C=1C=CC=CC=1COP(N(C(C)C)C(C)C)OCC1=CC=CC=C1 ANPWLBTUUNFQIO-UHFFFAOYSA-N 0.000 description 3
239000012071 phase Substances 0.000 description 3
UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 3
HRZFUMHJMZEROT-UHFFFAOYSA-L sodium disulfite Chemical compound [Na+].[Na+].[O-]S(=O)S([O-])(=O)=O HRZFUMHJMZEROT-UHFFFAOYSA-L 0.000 description 3
239000004296 sodium metabisulphite Substances 0.000 description 3
235000010262 sodium metabisulphite Nutrition 0.000 description 3
HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 3
238000004611 spectroscopical analysis Methods 0.000 description 3
239000001117 sulphuric acid Substances 0.000 description 3
235000011149 sulphuric acid Nutrition 0.000 description 3
LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 description 3
229960004740 voriconazole Drugs 0.000 description 3
QWUWMCYKGHVNAV-UHFFFAOYSA-N 1,2-dihydrostilbene Chemical group C=1C=CC=CC=1CCC1=CC=CC=C1 QWUWMCYKGHVNAV-UHFFFAOYSA-N 0.000 description 2
KJUGUADJHNHALS-UHFFFAOYSA-N 1H-tetrazole Chemical compound C=1N=NNN=1 KJUGUADJHNHALS-UHFFFAOYSA-N 0.000 description 2
241000228212 Aspergillus Species 0.000 description 2
CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 2
241000222120 Candida <Saccharomycetales> Species 0.000 description 2
LCGLNKUTAGEVQW-UHFFFAOYSA-N Dimethyl ether Chemical compound COC LCGLNKUTAGEVQW-UHFFFAOYSA-N 0.000 description 2
QXNVGIXVLWOKEQ-UHFFFAOYSA-N Disodium Chemical compound [Na][Na] QXNVGIXVLWOKEQ-UHFFFAOYSA-N 0.000 description 2
241000233866 Fungi Species 0.000 description 2
DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
241000282412 Homo Species 0.000 description 2
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
NTIZESTWPVYFNL-UHFFFAOYSA-N Methyl isobutyl ketone Chemical group CC(C)CC(C)=O NTIZESTWPVYFNL-UHFFFAOYSA-N 0.000 description 2
UIHCLUNTQKBZGK-UHFFFAOYSA-N Methyl isobutyl ketone Natural products CCC(C)C(C)=O UIHCLUNTQKBZGK-UHFFFAOYSA-N 0.000 description 2
241001480037 Microsporum Species 0.000 description 2
241000699670 Mus sp. Species 0.000 description 2
238000005481 NMR spectroscopy Methods 0.000 description 2
UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 2
241000223238 Trichophyton Species 0.000 description 2
229960001040 ammonium chloride Drugs 0.000 description 2
235000019270 ammonium chloride Nutrition 0.000 description 2
239000002585 base Substances 0.000 description 2
230000015572 biosynthetic process Effects 0.000 description 2
239000002775 capsule Substances 0.000 description 2
238000001816 cooling Methods 0.000 description 2
239000012043 crude product Substances 0.000 description 2
HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 2
229910000397 disodium phosphate Inorganic materials 0.000 description 2
235000019800 disodium phosphate Nutrition 0.000 description 2
238000001035 drying Methods 0.000 description 2
RFHAOTPXVQNOHP-UHFFFAOYSA-N fluconazole Chemical compound C1=NC=NN1CC(C=1C(=CC(F)=CC=1)F)(O)CN1C=NC=N1 RFHAOTPXVQNOHP-UHFFFAOYSA-N 0.000 description 2
229960004884 fluconazole Drugs 0.000 description 2
238000000338 in vitro Methods 0.000 description 2
VNWKTOKETHGBQD-UHFFFAOYSA-N methane Chemical compound C VNWKTOKETHGBQD-UHFFFAOYSA-N 0.000 description 2
239000012044 organic layer Substances 0.000 description 2
239000000546 pharmaceutical excipient Substances 0.000 description 2
229940002612 prodrug Drugs 0.000 description 2
239000000651 prodrug Substances 0.000 description 2
125000006239 protecting group Chemical group 0.000 description 2
229920006395 saturated elastomer Polymers 0.000 description 2
239000011734 sodium Substances 0.000 description 2
229910052708 sodium Inorganic materials 0.000 description 2
235000017557 sodium bicarbonate Nutrition 0.000 description 2
229960001407 sodium bicarbonate Drugs 0.000 description 2
229910000030 sodium bicarbonate Inorganic materials 0.000 description 2
239000001488 sodium phosphate Substances 0.000 description 2
GEHJYWRUCIMESM-UHFFFAOYSA-L sodium sulfite Chemical compound [Na+].[Na+].[O-]S([O-])=O GEHJYWRUCIMESM-UHFFFAOYSA-L 0.000 description 2
241000894007 species Species 0.000 description 2
238000003786 synthesis reaction Methods 0.000 description 2
JIAARYAFYJHUJI-UHFFFAOYSA-L zinc dichloride Chemical compound [Cl-].[Cl-].[Zn+2] JIAARYAFYJHUJI-UHFFFAOYSA-L 0.000 description 2
XUJHKPSBHDQIOD-UHFFFAOYSA-N (2-bromo-7,7-dimethyl-3-oxo-4-bicyclo[2.2.1]heptanyl)methanesulfonic acid Chemical compound C1CC2(CS(O)(=O)=O)C(=O)C(Br)C1C2(C)C XUJHKPSBHDQIOD-UHFFFAOYSA-N 0.000 description 1
ZZFCUESFXBCRSC-UHFFFAOYSA-N (2-chloro-6-fluorophenyl)methanol Chemical compound OCC1=C(F)C=CC=C1Cl ZZFCUESFXBCRSC-UHFFFAOYSA-N 0.000 description 1
MCTWTZJPVLRJOU-UHFFFAOYSA-N 1-methyl-1H-imidazole Chemical compound CN1C=CN=C1 MCTWTZJPVLRJOU-UHFFFAOYSA-N 0.000 description 1
NJAKCIUOTIPYED-UHFFFAOYSA-N 4-iodobenzoyl chloride Chemical compound ClC(=O)C1=CC=C(I)C=C1 NJAKCIUOTIPYED-UHFFFAOYSA-N 0.000 description 1
IKHGUXGNUITLKF-UHFFFAOYSA-N Acetaldehyde Chemical compound CC=O IKHGUXGNUITLKF-UHFFFAOYSA-N 0.000 description 1
229920001817 Agar Polymers 0.000 description 1
241000228197 Aspergillus flavus Species 0.000 description 1
BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
241000335423 Blastomyces Species 0.000 description 1
239000004381 Choline salt Substances 0.000 description 1
241000223203 Coccidioides Species 0.000 description 1
241000223205 Coccidioides immitis Species 0.000 description 1
229940126062 Compound A Drugs 0.000 description 1
201000007336 Cryptococcosis Diseases 0.000 description 1
241000221204 Cryptococcus neoformans Species 0.000 description 1
241001480035 Epidermophyton Species 0.000 description 1
241001480036 Epidermophyton floccosum Species 0.000 description 1
IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 1
PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 1
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
239000004471 Glycine Substances 0.000 description 1
239000007818 Grignard reagent Substances 0.000 description 1
NLDMNSXOCDLTTB-UHFFFAOYSA-N Heterophylliin A Natural products O1C2COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC2C(OC(=O)C=2C=C(O)C(O)=C(O)C=2)C(O)C1OC(=O)C1=CC(O)=C(O)C(O)=C1 NLDMNSXOCDLTTB-UHFFFAOYSA-N 0.000 description 1
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 1
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
241000124008 Mammalia Species 0.000 description 1
BZLVMXJERCGZMT-UHFFFAOYSA-N Methyl tert-butyl ether Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 description 1
206010065764 Mucosal infection Diseases 0.000 description 1
UQFQONCQIQEYPJ-UHFFFAOYSA-N N-methylpyrazole Chemical compound CN1C=CC=N1 UQFQONCQIQEYPJ-UHFFFAOYSA-N 0.000 description 1
239000007832 Na2SO4 Substances 0.000 description 1
235000010627 Phaseolus vulgaris Nutrition 0.000 description 1
244000046052 Phaseolus vulgaris Species 0.000 description 1
OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
239000004698 Polyethylene Substances 0.000 description 1
PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
241001238303 Turdus fuscater Species 0.000 description 1
201000007096 Vulvovaginal Candidiasis Diseases 0.000 description 1
CSWOUZHBOWSVMI-UHFFFAOYSA-N [2-(2,4-difluorophenyl)oxiran-2-yl]-(4-iodophenyl)methanone Chemical compound FC1=CC(F)=CC=C1C1(C(=O)C=2C=CC(I)=CC=2)OC1 CSWOUZHBOWSVMI-UHFFFAOYSA-N 0.000 description 1
241000222126 [Candida] glabrata Species 0.000 description 1
239000008272 agar Substances 0.000 description 1
239000003513 alkali Substances 0.000 description 1
125000000217 alkyl group Chemical group 0.000 description 1
238000004458 analytical method Methods 0.000 description 1
239000003429 antifungal agent Substances 0.000 description 1
239000013011 aqueous formulation Substances 0.000 description 1
239000012736 aqueous medium Substances 0.000 description 1
239000007864 aqueous solution Substances 0.000 description 1
125000004429 atom Chemical group 0.000 description 1
235000019445 benzyl alcohol Nutrition 0.000 description 1
125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
YOUGRGFIHBUKRS-UHFFFAOYSA-N benzyl(trimethyl)azanium Chemical compound C[N+](C)(C)CC1=CC=CC=C1 YOUGRGFIHBUKRS-UHFFFAOYSA-N 0.000 description 1
239000008280 blood Substances 0.000 description 1
210000004369 blood Anatomy 0.000 description 1
IYYIVELXUANFED-UHFFFAOYSA-N bromo(trimethyl)silane Chemical compound C[Si](C)(C)Br IYYIVELXUANFED-UHFFFAOYSA-N 0.000 description 1
230000003197 catalytic effect Effects 0.000 description 1
238000004296 chiral HPLC Methods 0.000 description 1
235000019417 choline salt Nutrition 0.000 description 1
239000012141 concentrate Substances 0.000 description 1
235000008504 concentrate Nutrition 0.000 description 1
238000007796 conventional method Methods 0.000 description 1
239000006071 cream Substances 0.000 description 1
KCIDZIIHRGYJAE-YGFYJFDDSA-L dipotassium;[(2r,3r,4s,5r,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl] phosphate Chemical class [K+].[K+].OC[C@H]1O[C@H](OP([O-])([O-])=O)[C@H](O)[C@@H](O)[C@H]1O KCIDZIIHRGYJAE-YGFYJFDDSA-L 0.000 description 1
BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 1
238000004821 distillation Methods 0.000 description 1
229940079593 drug Drugs 0.000 description 1
239000003814 drug Substances 0.000 description 1
125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
239000000706 filtrate Substances 0.000 description 1
239000012458 free base Substances 0.000 description 1
125000000524 functional group Chemical group 0.000 description 1
239000008103 glucose Substances 0.000 description 1
239000008187 granular material Substances 0.000 description 1
150000004795 grignard reagents Chemical class 0.000 description 1
229910052739 hydrogen Inorganic materials 0.000 description 1
239000001257 hydrogen Substances 0.000 description 1
DQKGOGJIOHUEGK-UHFFFAOYSA-M hydron;2-hydroxyethyl(trimethyl)azanium;carbonate Chemical compound OC([O-])=O.C[N+](C)(C)CCO DQKGOGJIOHUEGK-UHFFFAOYSA-M 0.000 description 1
HXJZHJLLMIGFCM-UHFFFAOYSA-N hydroxy-imino-di(propan-2-yloxy)-$l^{5}-phosphane Chemical compound CC(C)OP(N)(=O)OC(C)C HXJZHJLLMIGFCM-UHFFFAOYSA-N 0.000 description 1
239000003112 inhibitor Substances 0.000 description 1
230000002401 inhibitory effect Effects 0.000 description 1
238000002347 injection Methods 0.000 description 1
239000007924 injection Substances 0.000 description 1
239000002917 insecticide Substances 0.000 description 1
238000007918 intramuscular administration Methods 0.000 description 1
238000007912 intraperitoneal administration Methods 0.000 description 1
238000010253 intravenous injection Methods 0.000 description 1
238000002955 isolation Methods 0.000 description 1
239000008101 lactose Substances 0.000 description 1
229940057995 liquid paraffin Drugs 0.000 description 1
239000006210 lotion Substances 0.000 description 1
239000002609 medium Substances 0.000 description 1
238000002844 melting Methods 0.000 description 1
230000008018 melting Effects 0.000 description 1
LSEFCHWGJNHZNT-UHFFFAOYSA-M methyl(triphenyl)phosphanium;bromide Chemical compound [Br-].C=1C=CC=CC=1[P+](C=1C=CC=CC=1)(C)C1=CC=CC=C1 LSEFCHWGJNHZNT-UHFFFAOYSA-M 0.000 description 1
244000005700 microbiome Species 0.000 description 1
238000010899 nucleation Methods 0.000 description 1
239000012074 organic phase Substances 0.000 description 1
239000007800 oxidant agent Substances 0.000 description 1
230000001590 oxidative effect Effects 0.000 description 1
NXJCBFBQEVOTOW-UHFFFAOYSA-L palladium(2+);dihydroxide Chemical compound O[Pd]O NXJCBFBQEVOTOW-UHFFFAOYSA-L 0.000 description 1
NFHFRUOZVGFOOS-UHFFFAOYSA-N palladium;triphenylphosphane Chemical compound [Pd].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 NFHFRUOZVGFOOS-UHFFFAOYSA-N 0.000 description 1
239000012188 paraffin wax Substances 0.000 description 1
150000002978 peroxides Chemical class 0.000 description 1
150000004965 peroxy acids Chemical class 0.000 description 1
239000008194 pharmaceutical composition Substances 0.000 description 1
230000000144 pharmacologic effect Effects 0.000 description 1
AQSJGOWTSHOLKH-UHFFFAOYSA-N phosphite(3-) Chemical class [O-]P([O-])[O-] AQSJGOWTSHOLKH-UHFFFAOYSA-N 0.000 description 1
150000003014 phosphoric acid esters Chemical class 0.000 description 1
OJMIONKXNSYLSR-UHFFFAOYSA-N phosphorous acid Chemical compound OP(O)O OJMIONKXNSYLSR-UHFFFAOYSA-N 0.000 description 1
229910052698 phosphorus Inorganic materials 0.000 description 1
239000011574 phosphorus Substances 0.000 description 1
230000026731 phosphorylation Effects 0.000 description 1
238000006366 phosphorylation reaction Methods 0.000 description 1
229920000573 polyethylene Polymers 0.000 description 1
239000003755 preservative agent Substances 0.000 description 1
230000001681 protective effect Effects 0.000 description 1
238000000425 proton nuclear magnetic resonance spectrum Methods 0.000 description 1
238000000746 purification Methods 0.000 description 1
BBFCIBZLAVOLCF-UHFFFAOYSA-N pyridin-1-ium;bromide Chemical compound Br.C1=CC=NC=C1 BBFCIBZLAVOLCF-UHFFFAOYSA-N 0.000 description 1
150000003248 quinolines Chemical class 0.000 description 1
229910052938 sodium sulfate Inorganic materials 0.000 description 1
235000011152 sodium sulphate Nutrition 0.000 description 1
235000010265 sodium sulphite Nutrition 0.000 description 1
238000000527 sonication Methods 0.000 description 1
239000012258 stirred mixture Substances 0.000 description 1
125000005504 styryl group Chemical group 0.000 description 1
239000000126 substance Substances 0.000 description 1
230000004083 survival effect Effects 0.000 description 1
125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
150000003536 tetrazoles Chemical class 0.000 description 1
125000000437 thiazol-2-yl group Chemical group [H]C1=C([H])N=C(*)S1 0.000 description 1
230000000699 topical effect Effects 0.000 description 1
125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
239000008215 water for injection Substances 0.000 description 1
229940045860 white wax Drugs 0.000 description 1
235000005074 zinc chloride Nutrition 0.000 description 1
239000011592 zinc chloride Substances 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
- C07F9/65583—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system each of the hetero rings containing nitrogen as ring hetero atom
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6515—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having three nitrogen atoms as the only ring hetero atoms
- C07F9/6518—Five-membered rings
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

Chemical & Material Sciences (AREA)
Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Molecular Biology (AREA)
Biochemistry (AREA)
General Chemical & Material Sciences (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Chemical Kinetics & Catalysis (AREA)
Public Health (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Oncology (AREA)
Communicable Diseases (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Dermatology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Agricultural Chemicals And Associated Chemicals (AREA)
Plural Heterocyclic Compounds (AREA)

OA9800110A 1996-02-02 1998-07-10 Triazole derivatives useful in therapy. OA10711A (en)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
GBGB9602080.5A GB9602080D0 (en)	1996-02-02	1996-02-02	Pharmaceutical compounds

Publications (1)

Publication Number	Publication Date
OA10711A true OA10711A (en)	2001-06-04

Family

ID=10787975

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
OA9800110A OA10711A (en)	1996-02-02	1998-07-10	Triazole derivatives useful in therapy.

Country Status (42)

Country	Link
US (4)	US6790957B2 (pl)
EP (1)	EP0880533B1 (pl)
JP (1)	JP2959846B2 (pl)
KR (1)	KR100283546B1 (pl)
CN (1)	CN1085213C (pl)
AP (1)	AP678A (pl)
AT (1)	ATE219089T1 (pl)
AU (1)	AU709781B2 (pl)
BG (1)	BG63946B1 (pl)
BR (1)	BR9707257A (pl)
CA (1)	CA2240777C (pl)
CO (1)	CO4761066A1 (pl)
CZ (1)	CZ291431B6 (pl)
DE (1)	DE69713284T2 (pl)
DK (1)	DK0880533T3 (pl)
DZ (1)	DZ2172A1 (pl)
ES (1)	ES2175336T3 (pl)
GB (1)	GB9602080D0 (pl)
GT (1)	GT199700016A (pl)
HN (1)	HN1997000012A (pl)
HR (1)	HRP970063B1 (pl)
HU (1)	HU226133B1 (pl)
ID (1)	ID15858A (pl)
IL (3)	IL124865A (pl)
IS (1)	IS1995B (pl)
MY (1)	MY116849A (pl)
NO (1)	NO323771B1 (pl)
NZ (1)	NZ330654A (pl)
OA (1)	OA10711A (pl)
PL (1)	PL187237B1 (pl)
PT (1)	PT880533E (pl)
RS (1)	RS49526B (pl)
RU (1)	RU2176244C2 (pl)
SA (1)	SA97170578B1 (pl)
SI (1)	SI0880533T1 (pl)
SK (1)	SK283136B6 (pl)
TN (1)	TNSN97023A1 (pl)
TR (1)	TR199801440T2 (pl)
TW (1)	TW434247B (pl)
UA (1)	UA46828C2 (pl)
WO (1)	WO1997028169A1 (pl)
ZA (1)	ZA97826B (pl)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB9602080D0 (en) *	1996-02-02	1996-04-03	Pfizer Ltd	Pharmaceutical compounds
GB9713149D0 (en)	1997-06-21	1997-08-27	Pfizer Ltd	Pharmaceutical formulations
DE19751525C2 (de)	1997-11-20	2003-02-13	Bat Cigarettenfab Gmbh	Verfahren und Vorrichtung zur Regelung der Ausgangsfeuchte von Tabak
US6265584B1 (en)	1998-05-22	2001-07-24	Bristol-Myers Squibb Company	Water soluble prodrugs of azole compounds
WO2000030655A1 (en)	1998-11-20	2000-06-02	Bristol-Myers Squibb Company	Water soluble prodrugs of azole compounds
US6235728B1 (en)	1999-02-19	2001-05-22	Bristol-Myers Squibb Company	Water-soluble prodrugs of azole compounds
KR20010050557A (ko) *	1999-09-29	2001-06-15	타이도 나오카타	아졸 유도체 또는 그의 염
US6362172B2 (en)	2000-01-20	2002-03-26	Bristol-Myers Squibb Company	Water soluble prodrugs of azole compounds
US6448401B1 (en) *	2000-11-20	2002-09-10	Bristol-Myers Squibb Company	Process for water soluble azole compounds
US7540402B2 (en) *	2001-06-29	2009-06-02	Kva, Inc.	Method for controlling weld metal microstructure using localized controlled cooling of seam-welded joints
US7323572B2 (en)	2002-07-16	2008-01-29	Pfizer Inc	Process for controlling the hydrate mix of a compound
EP1646284A4 (en) *	2003-07-18	2008-09-24	Rhode Island Education	AZOL DERIVATIVES AND METHOD FOR THEIR PREPARATION
KR20070085093A (ko) *	2004-03-24	2007-08-27	파스젠, 엘엘씨.	Ａｍｐ-활성화 단백질 키나아제의 약리학적 저해에 의한신규한 신경 보호 방법
CN1303073C (zh) *	2005-05-31	2007-03-07	中国人民解放军第二军医大学	取代三唑酮苄胺三唑醇类抗真菌化合物及其制备方法
EP1964843B1 (en) *	2005-12-20	2013-08-28	Eisai R&D Management Co., Ltd.	Process for production of water-soluble azole prodrug
EP1968990B1 (en)	2005-12-27	2015-02-11	Otsuka Pharmaceutical Co., Ltd.	Water-soluble benzoazepine compound and its pharmaceutical composition
KR101250632B1 (ko) *	2006-02-22	2013-04-03	에자이 알앤드디 매니지먼트 가부시키가이샤	안정화 의약 조성물
KR100889937B1 (ko) *	2007-08-06	2009-03-20	한미약품 주식회사	보리코나졸의 제조방법
WO2009129300A2 (en) *	2008-04-15	2009-10-22	Schering Corporation	High density compositions containing posaconazole and formulations comprising the same
CN101575330B (zh) *	2008-05-05	2012-10-31	丽珠医药集团股份有限公司	伏立康唑广谱抗真菌药物化合物、其组合物及用途
WO2011064558A2 (en)	2009-11-30	2011-06-03	Cipla Limited	Pharmaceutical composition
EP2723452A2 (en)	2011-06-22	2014-04-30	Vyome Biosciences Pvt Ltd	Conjugate-based antifungal and antibacterial prodrugs
EP2561863A1 (en)	2011-08-22	2013-02-27	Farmaprojects, S.A.U.	Pharmaceutical compositions comprising voriconazole
IN2014DN06792A (pl) *	2012-01-20	2015-05-22	Viamet Pharmaceuticals Inc
KR102236462B1 (ko) *	2012-03-19	2021-04-08	시다라 세라퓨틱스, 인코포레이티드	에키노칸딘 계열의 화합물에 대한 투여 용법
CN103864844B (zh) *	2012-12-09	2016-10-05	正大天晴药业集团股份有限公司	一种福司氟康唑的制备方法
CN103304600B (zh) *	2013-03-04	2018-05-25	陕西合成药业股份有限公司	一种伏立康唑磷酸酯三水合物及其制备方法和用途
RU2719579C2 (ru) *	2013-03-14	2020-04-21	Сидара Терапьютикс, Инк.	Режимы дозирования для соединений класса эхинокандинов
US20140275122A1 (en)	2013-03-14	2014-09-18	Fresenius Kabi Usa, Llc	Voriconazole Formulations
WO2014195872A1 (en)	2013-06-04	2014-12-11	Vyome Biosciences Pvt. Ltd.	Coated particles and compositions comprising same
CN103524560A (zh) *	2013-09-28	2014-01-22	陕西合成药业有限公司	伏立康磷酸酯钠水合物及其多晶型
CN104650140B (zh) *	2013-11-18	2017-11-10	正大天晴药业集团股份有限公司	一种高纯度福司氟康唑的制备方法
CN113559105B (zh)	2014-01-29	2026-06-23	维奥姆治疗有限公司	抗性痤疮的治疗
CN104860992A (zh) *	2014-02-25	2015-08-26	陕西合成药业股份有限公司	一种高纯度福司氟康唑制备方法
CN105985377A (zh) *	2015-02-09	2016-10-05	陕西合成药业股份有限公司	一种福司氟康唑盐水合物及其制备方法
CN106279280A (zh) *	2015-05-25	2017-01-04	西藏卫信康医药股份有限公司	一种化合物及其制备方法和应用
CN106518922A (zh) *	2015-09-12	2017-03-22	陕西合成药业股份有限公司	一种三唑类化合物及其制备方法和用途
CN106546668A (zh) *	2015-09-22	2017-03-29	陕西合成药业股份有限公司	一种分离福司氟康唑或其药用盐有关物质的hplc方法
CN105237569B (zh) *	2015-10-21	2017-07-25	西南科技大学	一种制备2，4‑二氟‑α，α‑二（1氢‑1，2，4‑三唑‑1‑基甲基）苯甲醇磷酸二苄酯的合成方法
CN105753902B (zh) *	2016-04-11	2017-08-25	浙江诚意药业股份有限公司	一种福司氟康唑的制备方法
CN108676031A (zh) *	2018-05-29	2018-10-19	重庆威鹏药业有限公司	水溶性三唑类抗真菌膦酸化合物及其制备方法和应用
CN111171075B (zh) *	2020-04-03	2022-07-12	北京四环生物制药有限公司	一种福司氟康唑的制备方法

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB2099818A (en) *	1981-06-06	1982-12-15	Pfizer Ltd	Triazoles
US4528284A (en) *	1982-10-15	1985-07-09	Ciba-Geigy Corporation	Fungicidal 2-(azolylmethyl-1'-yl)-2-aryl-2-(cyano, alkoxycarbonyl, alkylthiocarbonyl and aminocarbonyl)-2-phosphorus acid esters
US4952232A (en) *	1987-04-29	1990-08-28	E. I. Du Pont De Nemours And Company	Antifungal carbinols
US5043273A (en) *	1989-08-17	1991-08-27	Monsanto Company	Phosphorylated glycosidase inhibitor prodrugs
GB9002375D0 (en) *	1990-02-02	1990-04-04	Pfizer Ltd	Triazole antifungal agents
US5278175A (en) *	1990-02-02	1994-01-11	Pfizer Inc.	Triazole antifungal agents
TW211006B (pl) *	1990-08-24	1993-08-11	Mochida Pharm Co Ltd
TW218017B (pl) *	1992-04-28	1993-12-21	Takeda Pharm Industry Co Ltd
US5358939A (en) *	1992-06-25	1994-10-25	Rohm And Haas Company	Fungicidal 2-aryl-2,2-disubstituted ethyl-1,2,4-triazoles
SG48386A1 (en) *	1994-01-24	1998-04-17	Janssen Pharmaceutica Nv	Watersoluble azole antifungals
NZ270418A (en) *	1994-02-07	1997-09-22	Eisai Co Ltd	Polycyclic triazole & imidazole derivatives, antifungal compositions
CA2182698A1 (en) *	1994-02-25	1995-08-31	Jun Sato	Injectable emulsions containing antifungal triazole derivatives
GB9512961D0 (en) *	1995-06-26	1995-08-30	Pfizer Ltd	Antifungal agents
FR2741061B1 (fr) *	1995-11-13	1998-03-20	Alcatel Fibres Optiques	Procede de fabrication d'une fibre optique monomode et amplificateur optique utilisant une telle fibre
GB9602080D0 (en) *	1996-02-02	1996-04-03	Pfizer Ltd	Pharmaceutical compounds
US5767977A (en) *	1996-12-19	1998-06-16	Hewlett-Packard Co.	Method and apparatus for a carriage latch and power cord lock-out system for an optical scanner

1996
- 1996-02-02 GB GBGB9602080.5A patent/GB9602080D0/en active Pending
- 1996-12-27 TW TW085116150A patent/TW434247B/zh not_active IP Right Cessation
1997
- 1997-01-27 SA SA97170578A patent/SA97170578B1/ar unknown
- 1997-01-27 BR BR9707257A patent/BR9707257A/pt active Search and Examination
- 1997-01-27 ES ES97902288T patent/ES2175336T3/es not_active Expired - Lifetime
- 1997-01-27 RU RU98116435/04A patent/RU2176244C2/ru not_active IP Right Cessation
- 1997-01-27 CA CA002240777A patent/CA2240777C/en not_active Expired - Fee Related
- 1997-01-27 SK SK1022-98A patent/SK283136B6/sk not_active IP Right Cessation
- 1997-01-27 JP JP9527312A patent/JP2959846B2/ja not_active Expired - Lifetime
- 1997-01-27 SI SI9730341T patent/SI0880533T1/xx unknown
- 1997-01-27 IL IL12486597A patent/IL124865A/en not_active IP Right Cessation
- 1997-01-27 PL PL97328436A patent/PL187237B1/pl not_active IP Right Cessation
- 1997-01-27 PT PT97902288T patent/PT880533E/pt unknown
- 1997-01-27 DK DK97902288T patent/DK0880533T3/da active
- 1997-01-27 NZ NZ330654A patent/NZ330654A/xx unknown
- 1997-01-27 AU AU15985/97A patent/AU709781B2/en not_active Ceased
- 1997-01-27 TR TR1998/01440T patent/TR199801440T2/xx unknown
- 1997-01-27 UA UA98094671A patent/UA46828C2/uk unknown
- 1997-01-27 WO PCT/EP1997/000445 patent/WO1997028169A1/en not_active Ceased
- 1997-01-27 CN CN97192005A patent/CN1085213C/zh not_active Expired - Lifetime
- 1997-01-27 EP EP97902288A patent/EP0880533B1/en not_active Expired - Lifetime
- 1997-01-27 AT AT97902288T patent/ATE219089T1/de not_active IP Right Cessation
- 1997-01-27 CZ CZ19982420A patent/CZ291431B6/cs not_active IP Right Cessation
- 1997-01-27 DE DE69713284T patent/DE69713284T2/de not_active Expired - Fee Related
- 1997-01-27 HN HN1997000012A patent/HN1997000012A/es unknown
- 1997-01-27 HU HU9900949A patent/HU226133B1/hu not_active IP Right Cessation
- 1997-01-27 KR KR1019980705961A patent/KR100283546B1/ko not_active Expired - Fee Related
- 1997-01-28 RS YU2997A patent/RS49526B/sr unknown
- 1997-01-29 DZ DZ970017A patent/DZ2172A1/fr active
- 1997-01-29 TN TNTNSN97023A patent/TNSN97023A1/fr unknown
- 1997-01-30 AP APAP/P/1997/000923A patent/AP678A/en active
- 1997-01-30 GT GT199700016A patent/GT199700016A/es unknown
- 1997-01-31 HR HR970063A patent/HRP970063B1/xx not_active IP Right Cessation
- 1997-01-31 CO CO97004868A patent/CO4761066A1/es unknown
- 1997-01-31 MY MYPI97000389A patent/MY116849A/en unknown
- 1997-01-31 ZA ZA97826A patent/ZA97826B/xx unknown
- 1997-01-31 ID IDP970289A patent/ID15858A/id unknown
1998
- 1998-06-11 IL IL13313598A patent/IL133135A/xx not_active IP Right Cessation
- 1998-06-26 IS IS4785A patent/IS1995B/is unknown
- 1998-07-06 BG BG102603A patent/BG63946B1/bg unknown
- 1998-07-10 OA OA9800110A patent/OA10711A/en unknown
- 1998-08-03 NO NO19983560A patent/NO323771B1/no not_active IP Right Cessation
1999
- 1999-11-25 IL IL13313599A patent/IL133135A0/xx unknown
2003
- 2003-01-09 US US10/339,087 patent/US6790957B2/en not_active Expired - Fee Related
2004
- 2004-03-26 US US10/810,100 patent/US6977302B2/en not_active Expired - Fee Related
2005
- 2005-01-28 US US11/046,266 patent/US20050130940A1/en not_active Abandoned
2006
- 2006-09-29 US US11/540,375 patent/US20070027115A1/en not_active Abandoned

Also Published As

Publication number	Publication date
CO4761066A1 (es)	1999-04-27
NZ330654A (en)	1999-08-30
ID15858A (id)	1997-08-14
CZ242098A3 (cs)	1999-05-12
AP678A (en)	1998-09-28
PL328436A1 (en)	1999-02-01
IL124865A0 (en)	1999-01-26
HUP9900949A3 (en)	2001-08-28
KR19990082233A (ko)	1999-11-25
HK1018217A1 (en)	1999-12-17
SK102298A3 (en)	1999-08-06
CA2240777C (en)	2002-06-11
ATE219089T1 (de)	2002-06-15
PT880533E (pt)	2002-09-30
AP9700923A0 (en)	1997-01-31
HN1997000012A (es)	1997-06-26
HRP970063A2 (en)	1998-06-30
WO1997028169A1 (en)	1997-08-07
CN1210540A (zh)	1999-03-10
CN1085213C (zh)	2002-05-22
EP0880533B1 (en)	2002-06-12
BG102603A (en)	1999-03-31
IL133135A0 (en)	2001-03-19
JPH10512599A (ja)	1998-12-02
PL187237B1 (pl)	2004-06-30
IS1995B (is)	2005-03-15
DE69713284D1 (de)	2002-07-18
YU2997A (sh)	2000-10-30
AU709781B2 (en)	1999-09-09
ES2175336T3 (es)	2002-11-16
NO323771B1 (no)	2007-07-02
CZ291431B6 (cs)	2003-03-12
BG63946B1 (bg)	2003-07-31
TW434247B (en)	2001-05-16
HRP970063B1 (en)	2001-12-31
US20040236105A1 (en)	2004-11-25
US6977302B2 (en)	2005-12-20
IL124865A (en)	2002-03-10
IS4785A (is)	1998-06-26
HU226133B1 (en)	2008-05-28
US20030144250A1 (en)	2003-07-31
JP2959846B2 (ja)	1999-10-06
US20070027115A1 (en)	2007-02-01
US20050130940A1 (en)	2005-06-16
MY116849A (en)	2004-04-30
KR100283546B1 (ko)	2001-04-02
DZ2172A1 (fr)	2002-12-01
NO983560L (no)	1998-08-03
AU1598597A (en)	1997-08-22
SI0880533T1 (en)	2002-08-31
DE69713284T2 (de)	2003-03-27
SK283136B6 (sk)	2003-03-04
GB9602080D0 (en)	1996-04-03
SA97170578B1 (ar)	2006-01-28
RU2176244C2 (ru)	2001-11-27
HUP9900949A2 (hu)	2001-05-28
RS49526B (sr)	2006-12-15
GT199700016A (es)	1998-07-24
UA46828C2 (uk)	2002-06-17
ZA97826B (en)	1998-07-31
NO983560D0 (no)	1998-08-03
TNSN97023A1 (fr)	2005-03-15
US6790957B2 (en)	2004-09-14
DK0880533T3 (da)	2002-07-15
BR9707257A (pt)	1999-04-06
CA2240777A1 (en)	1997-08-07
TR199801440T2 (xx)	1998-10-21
EP0880533A1 (en)	1998-12-02
IL133135A (en)	2003-07-06

Publication	Publication Date	Title
EP0880533B1 (en)	2002-06-12	Triazole derivatives useful in therapy
CA2397734C (en)	2010-08-17	Water soluble prodrugs of azole compounds
AU2002213317B2 (en)	2007-03-15	Improved process for water soluble azole compounds
AU2006241694B2 (en)	2011-10-20	Mono-lysine salts of azole compounds
HK1018217B (zh)	2002-11-01	用於治疗的三唑衍生物
FR2694936A1 (fr)	1994-02-25	Dérivés substitués du désoxy-myoinositol, procédé pour leur préparation et leur utilisation dans des médicaments.